Ability of a Cat Food to Reduce Respiratory Symptoms in Cat Allergic Patients (NCT05656482) | Clinical Trial Compass
UnknownNot Applicable
Ability of a Cat Food to Reduce Respiratory Symptoms in Cat Allergic Patients
France50 participantsStarted 2022-05-06
Plain-language summary
Cat allergy is the most common animal allergy, affecting approximately 1 in 5 adults worldwide. The prevalence of allergy to furry animals is increasing, and cat allergy is a major risk factor for the development of asthma and rhinitis.
Fel-d1 is the major feline allergen, to which 95% of cat allergic people react. All cats produce Fel-d1 regardless of breed, age, coat type, sex or weight. Fel-d1 is contained primarily in the saliva and sebum of cats.
This allergy manifests itself as allergic rhinitis (AR) (sneezing, cold, coughing, conjunctivitis with watering and itching), severe asthma, and irritation and swelling of the skin when scratched.
A new approach to managing cat allergies is to neutralize the allergens at the source by feeding domestic cats a diet containing anti-Fel-d1 IgY antibodies. The purpose of this pilot study is to determine whether feeding domestic cats a food containing an egg product with anti-Fel d1 IgY (PRO PLAN® LIVECLEAT®) induces a reduction of allergic symptoms in their owners.
Who can participate
Age range
18 Years – 70 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Uncontrolled allergic rhinitis (with or without treatment)
* Persistent allergic rhinitis with worsening of symptoms upon exposure to cats
* Presence of one or two cats in the household, whose diet consists mainly of dry kibble
* Agreement of the patient to change the food of the cat(s) and to feed it exclusively with the test kibbles during the study.
* Diagnosis of cat allergy defined by a positive prick test to standardized cat allergen or cat-specific IgE.
* Absence of allergy to pollens emitted in the region during the 4 months following the inclusion date, confirmed by a negative skin test.
* Person owning an android and/or IOS smartphone and having the possibility to connect to the internet (via phone subscription or WIFI connection),
* Person who agrees to install the MASK-air application (medical device) on his personal smartphone,
* Person having read and understood the information note and having signed their participation agreement before any specific procedure of the study.
Exclusion Criteria:
* Person planning to be away from the cat(s) for more than one week/month in the 4 months following the inclusion visit
* Patient who has had a new cat in the home for less than one month
* Patient in regular contact with other animals to which they are allergic
* Patient with uncontrolled asthma
* Patient receiving immunotherapy for cat allergies
* Patient participating or having participated in an allergic rhinitis study within the last 30 days or…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change of the global Visual Analogic Scale (VAS) mean from Baseline period (Day 0- Day 15) at end period (Day 98-Day112)
Timeframe: Baseline (Day 0- Day 15) and observation period (Day 98-Day112)